Comparison of stage at diagnosis of cancer in patients who are on dialysis versus the general population

Shilpa Taneja, Sreedhar Mandayam, Zainab Z. Kayani, Yong Fang Kuo, Vahakn B. Shahinian

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Background and Objectives: Frequent medical encounters in patients with ESRD on dialysis may allow early detection of malignancies despite low rates of cancer screening in this population. It is therefore unclear whether dialysis patients are disadvantaged in terms of cancer diagnosis. This study compared stage at diagnosis of cancer in a population-based sample of patients with ESRD versus the general population. Design, Setting, Participants, & Measurements: The Surveillance, Epidemiology, and End Results Medicare database was used to identify patients with ESRD and incident cancers from 1992 through 1999. Modified Poisson regression models were used to predict nonlocalized stage of cancer at diagnosis in patients with ESRD versus the general population, adjusting for demographics, cancer site, region, year of diagnosis, and comorbidity. Two general population comparisons were used: Standardized Surveillance, Epidemiology, and End Results public-use data and Medicare control subjects without ESRD matched 3:1 to patients with ESRD. Results: A total of 1629 patients with ESRD and incident cancer were identified. Overall, the likelihood of nonlocalized stage at diagnosis was not significantly different for patients with ESRD versus the standardized Surveillance, Epidemiology, and End Results general population or matched Medicare control subjects. Stratifying by cancer site, colorectal cancers were significantly more likely to be diagnosed earlier in the ESRD group, whereas prostate cancers were significantly more likely to be diagnosed at a later stage. Conclusions: With the exception of prostate cancer, patients with ESRD are not more likely to present with later stage malignancies compared with the general population.

Original languageEnglish (US)
Pages (from-to)1008-1013
Number of pages6
JournalClinical Journal of the American Society of Nephrology
Volume2
Issue number5
DOIs
StatePublished - Sep 2007

Fingerprint

Chronic Kidney Failure
Dialysis
Population
Neoplasms
Medicare
Epidemiology
Prostatic Neoplasms
Vulnerable Populations
Early Detection of Cancer
Comorbidity
Colorectal Neoplasms
Demography
Databases

ASJC Scopus subject areas

  • Nephrology
  • Transplantation
  • Epidemiology
  • Critical Care and Intensive Care Medicine
  • Medicine(all)

Cite this

Comparison of stage at diagnosis of cancer in patients who are on dialysis versus the general population. / Taneja, Shilpa; Mandayam, Sreedhar; Kayani, Zainab Z.; Kuo, Yong Fang; Shahinian, Vahakn B.

In: Clinical Journal of the American Society of Nephrology, Vol. 2, No. 5, 09.2007, p. 1008-1013.

Research output: Contribution to journalArticle

Taneja, Shilpa ; Mandayam, Sreedhar ; Kayani, Zainab Z. ; Kuo, Yong Fang ; Shahinian, Vahakn B. / Comparison of stage at diagnosis of cancer in patients who are on dialysis versus the general population. In: Clinical Journal of the American Society of Nephrology. 2007 ; Vol. 2, No. 5. pp. 1008-1013.
@article{895af88cb5854f3e91967e423990c1d5,
title = "Comparison of stage at diagnosis of cancer in patients who are on dialysis versus the general population",
abstract = "Background and Objectives: Frequent medical encounters in patients with ESRD on dialysis may allow early detection of malignancies despite low rates of cancer screening in this population. It is therefore unclear whether dialysis patients are disadvantaged in terms of cancer diagnosis. This study compared stage at diagnosis of cancer in a population-based sample of patients with ESRD versus the general population. Design, Setting, Participants, & Measurements: The Surveillance, Epidemiology, and End Results Medicare database was used to identify patients with ESRD and incident cancers from 1992 through 1999. Modified Poisson regression models were used to predict nonlocalized stage of cancer at diagnosis in patients with ESRD versus the general population, adjusting for demographics, cancer site, region, year of diagnosis, and comorbidity. Two general population comparisons were used: Standardized Surveillance, Epidemiology, and End Results public-use data and Medicare control subjects without ESRD matched 3:1 to patients with ESRD. Results: A total of 1629 patients with ESRD and incident cancer were identified. Overall, the likelihood of nonlocalized stage at diagnosis was not significantly different for patients with ESRD versus the standardized Surveillance, Epidemiology, and End Results general population or matched Medicare control subjects. Stratifying by cancer site, colorectal cancers were significantly more likely to be diagnosed earlier in the ESRD group, whereas prostate cancers were significantly more likely to be diagnosed at a later stage. Conclusions: With the exception of prostate cancer, patients with ESRD are not more likely to present with later stage malignancies compared with the general population.",
author = "Shilpa Taneja and Sreedhar Mandayam and Kayani, {Zainab Z.} and Kuo, {Yong Fang} and Shahinian, {Vahakn B.}",
year = "2007",
month = "9",
doi = "10.2215/CJN.00310107",
language = "English (US)",
volume = "2",
pages = "1008--1013",
journal = "Clinical journal of the American Society of Nephrology : CJASN",
issn = "1555-9041",
publisher = "American Society of Nephrology",
number = "5",

}

TY - JOUR

T1 - Comparison of stage at diagnosis of cancer in patients who are on dialysis versus the general population

AU - Taneja, Shilpa

AU - Mandayam, Sreedhar

AU - Kayani, Zainab Z.

AU - Kuo, Yong Fang

AU - Shahinian, Vahakn B.

PY - 2007/9

Y1 - 2007/9

N2 - Background and Objectives: Frequent medical encounters in patients with ESRD on dialysis may allow early detection of malignancies despite low rates of cancer screening in this population. It is therefore unclear whether dialysis patients are disadvantaged in terms of cancer diagnosis. This study compared stage at diagnosis of cancer in a population-based sample of patients with ESRD versus the general population. Design, Setting, Participants, & Measurements: The Surveillance, Epidemiology, and End Results Medicare database was used to identify patients with ESRD and incident cancers from 1992 through 1999. Modified Poisson regression models were used to predict nonlocalized stage of cancer at diagnosis in patients with ESRD versus the general population, adjusting for demographics, cancer site, region, year of diagnosis, and comorbidity. Two general population comparisons were used: Standardized Surveillance, Epidemiology, and End Results public-use data and Medicare control subjects without ESRD matched 3:1 to patients with ESRD. Results: A total of 1629 patients with ESRD and incident cancer were identified. Overall, the likelihood of nonlocalized stage at diagnosis was not significantly different for patients with ESRD versus the standardized Surveillance, Epidemiology, and End Results general population or matched Medicare control subjects. Stratifying by cancer site, colorectal cancers were significantly more likely to be diagnosed earlier in the ESRD group, whereas prostate cancers were significantly more likely to be diagnosed at a later stage. Conclusions: With the exception of prostate cancer, patients with ESRD are not more likely to present with later stage malignancies compared with the general population.

AB - Background and Objectives: Frequent medical encounters in patients with ESRD on dialysis may allow early detection of malignancies despite low rates of cancer screening in this population. It is therefore unclear whether dialysis patients are disadvantaged in terms of cancer diagnosis. This study compared stage at diagnosis of cancer in a population-based sample of patients with ESRD versus the general population. Design, Setting, Participants, & Measurements: The Surveillance, Epidemiology, and End Results Medicare database was used to identify patients with ESRD and incident cancers from 1992 through 1999. Modified Poisson regression models were used to predict nonlocalized stage of cancer at diagnosis in patients with ESRD versus the general population, adjusting for demographics, cancer site, region, year of diagnosis, and comorbidity. Two general population comparisons were used: Standardized Surveillance, Epidemiology, and End Results public-use data and Medicare control subjects without ESRD matched 3:1 to patients with ESRD. Results: A total of 1629 patients with ESRD and incident cancer were identified. Overall, the likelihood of nonlocalized stage at diagnosis was not significantly different for patients with ESRD versus the standardized Surveillance, Epidemiology, and End Results general population or matched Medicare control subjects. Stratifying by cancer site, colorectal cancers were significantly more likely to be diagnosed earlier in the ESRD group, whereas prostate cancers were significantly more likely to be diagnosed at a later stage. Conclusions: With the exception of prostate cancer, patients with ESRD are not more likely to present with later stage malignancies compared with the general population.

UR - http://www.scopus.com/inward/record.url?scp=34548826256&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548826256&partnerID=8YFLogxK

U2 - 10.2215/CJN.00310107

DO - 10.2215/CJN.00310107

M3 - Article

C2 - 17702737

AN - SCOPUS:34548826256

VL - 2

SP - 1008

EP - 1013

JO - Clinical journal of the American Society of Nephrology : CJASN

JF - Clinical journal of the American Society of Nephrology : CJASN

SN - 1555-9041

IS - 5

ER -